15 - Valent Pneumococcal Conjugate Vaccine (VAXNEUVANCE™)
**Please enter the Cathay membership number in the "Company Name / Cathay membership number" field on the billing info page. The first name and last name must be the same as the registered name of the Cathay membership. Additionally, enter "Cathay" in the "Offer No. /Rewards Programme" to receive Asia Miles rewards of HK$3 = 1 mile.
Standard Chartered Cathay Mastercard® Bonus Asia Miles offer#: please enter the "first 6-digit of your Standard Chartered Cathay Mastercard®” in the "Offer No. /Rewards Programme" code on the billing info page.
No reissue or change will be made if requested information is missing or if the data is incorrect during checkout.**
#To enjoy 50% bonus miles of designated healthcare services or vaccines, customers need to use Standard Chartered Cathay Mastercard® upon check out.
There are over 100 serotypes of pneumococcus, of which serotype 3 is the biggest threat. Regardless of age, most severe and hospitalised cases of pneumococcal infection are caused by serotype 3. Streptococcus pneumoniae causes a wide range of diseases, including middle ear infection (acute otitis media), pneumonia, and various forms of invasive pneumococcal disease (IPD), such as meningitis and bloodstream infection (bacteremia and sepsis). Pneumococci are commonly found in the nose and throat of healthy individuals, especially children. Transmission occurs primarily through droplets generated by coughing and sneezing, close contact with infected individuals, or contact with contaminated objects. Pneumococcal vaccination is one of the safe and effective means of preventing pneumococcal diseases. You should talk to your doctor to find out if you need to be vaccinated against pneumococcal disease.
15-Valent Pneumococcal Conjugate Vaccine (VAXNEUVANCE™) is now indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals. VAXNEUVANCE™ specifically targets serotype 3 pneumococcus and helps prevent pneumonia and invasive disease (meningitis, septicaemia, etc.) caused by pneumococcus (including 15 serotypes).
Highlights:
- According to the recommendation made by the Scientific Committee on Vaccine Preventable Diseases (SCVPD) under the Centre for Health Protection of the Department of Health (DH), VAXNEUVANCE™ induces high immunogenicity against serotype 3 which is believed to be more effective in preventing IPD caused by this serotype.
- It is approved for use by the US FDA and the EU, and is widely used in European and American countries such as the US, the UK and Canada, as well as Australia.
- This is a registered pharmaceutical product approved by the Pharmacy and Poisons Board of Hong Kong. It meets the criteria for safety, efficacy, and quality.
How:
- Intramuscular Injection
- Single-dose / multiple-doses administration (where applicable)
Recommended for
- Individuals aged 6 weeks or above and under 2 years old:
Standard Regimen* (2 primary doses + 1 booster dose)
- First primary dose at 2 months of age
- Second primary dose at 4 months of age
- One booster dose at 12 months of age
* A catch-up schedule is to be followed for any missed or delayed doses. Please consult a medical practitioner for the applicable schedule of vaccine administration.
- Individuals aged 2 years old or above: Single Dose
Designated Quality HealthCare Medical Centres:
Click here for more details.
Scan & Book appointment via QHMS mobile app or WhatsApp 8301-8301
Recommended for
Individuals aged 6 weeks or above
